{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T13:32:11Z","timestamp":1793367131615,"version":"4.5.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T00:00:00Z","timestamp":1785024000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ejso.2026.112001","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T04:55:47Z","timestamp":1783918547000},"page":"112001","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prediction of perioperative FLOT outcomes in Resectable Gastric and GEJ Adenocarcinoma with pathologic and molecular features: A Retrospective Real-World Cohort Study"],"prefix":"10.1016","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3814-5726","authenticated-orcid":false,"given":"Annamaria","family":"Agnes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6736-0383","authenticated-orcid":false,"given":"Laura","family":"Lorenzon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Moretta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Strippoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmelo","family":"Pozzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9089-5084","authenticated-orcid":false,"given":"Riccardo","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavio","family":"Tirelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4109-9727","authenticated-orcid":false,"given":"Lorenzo","family":"Ferri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6085-9296","authenticated-orcid":false,"given":"Lorenzo","family":"Rocca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7148-0227","authenticated-orcid":false,"given":"Francesca","family":"Chicchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"D'Ugo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giampaolo","family":"Tortora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Persiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2470-7858","authenticated-orcid":false,"given":"Alberto","family":"Biondi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10184","key":"10.1016\/j.ejso.2026.112001_bib1","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"Al-Batran","year":"2019","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.ejso.2026.112001_bib2","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1097\/SLA.0000000000005097","article-title":"FLOT-regimen Chemotherapy and Transthoracic en bloc Resection for Esophageal and Junctional Adenocarcinoma","volume":"274","author":"Donlon","year":"2021","journal-title":"Ann Surg"},{"issue":"4","key":"10.1016\/j.ejso.2026.112001_bib3","article-title":"Pathological response guides adjuvant 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy in surgically resected gastro-oesophageal cancer (SPACE-FLOT): international cohort study","volume":"112","year":"2025","journal-title":"Br J Surg"},{"issue":"8","key":"10.1016\/j.ejso.2026.112001_bib4","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.3390\/jcm9082654","article-title":"Pattern of recurrence and patient survival after perioperative chemotherapy with 5-FU, leucovorin, oxaliplatin and docetaxel (FLOT) for locally advanced esophagogastric adenocarcinoma in patients treated outside clinical trials","volume":"9","author":"Glatz","year":"2020","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.ejso.2026.112001_bib5","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1186\/s12885-021-08768-7","article-title":"Results of the observational prospective RealFLOT study","volume":"21","author":"Giommoni","year":"2021","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.ejso.2026.112001_bib6","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00423-023-02822-7","article-title":"Perioperative chemotherapy with 5-FU, leucovorin, oxaliplatin, and docetaxel (FLOT) for esophagogastric adenocarcinoma: ten years real-life experience from a surgical perspective","volume":"408","author":"Sisic","year":"2023","journal-title":"Langenbecks Arch Surg"},{"issue":"9","key":"10.1016\/j.ejso.2026.112001_bib7","doi-asserted-by":"crossref","first-page":"6601","DOI":"10.1007\/s00432-023-04636-y","article-title":"Pattern of recurrence and overall survival in esophagogastric cancer after perioperative FLOT and clinical outcomes in MSI-H population: the PROSECCO study","volume":"149","author":"Nappo","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.ejso.2026.112001_bib8","doi-asserted-by":"crossref","first-page":"322","DOI":"10.2340\/1651-226X.2024.35431","article-title":"Implementation of perioperative FLOT compared to ECX\/EOX chemotherapy regimens in resectable esophagogastric adenocarcinomas: an analysis of real-world data","volume":"63","author":"Egebjerg","year":"2024","journal-title":"Acta Oncol"},{"issue":"7","key":"10.1016\/j.ejso.2026.112001_bib9","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1158\/1078-0432.CCR-22-2920","article-title":"Event-free survival as a surrogate for overall survival in gastric and gastroesophageal junction adenocarcinoma: a meta-analysis in the neoadjuvant \u00b1 adjuvant setting","volume":"29","author":"Matterhorn","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.ejso.2026.112001_bib10","doi-asserted-by":"crossref","first-page":"4197","DOI":"10.1038\/s41591-025-03979-y","article-title":"Perioperative pembrolizumab, trastuzumab and FLOT in HER2-positive localized esophagogastric adenocarcinoma: a phase 2 trial","volume":"31","author":"Stein","year":"2025","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.ejso.2026.112001_bib11","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1200\/JCO.23.00975","article-title":"Perioperative atezolizumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable esophagogastric cancer: interim results from the randomized, multicenter, phase II\/III DANTE\/IKF-s633 trial","volume":"42","author":"Lorenzen","year":"2024","journal-title":"J Clin Oncol"},{"issue":"10389","key":"10.1016\/j.ejso.2026.112001_bib12","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","article-title":"Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial","volume":"401","author":"Shitara","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ejso.2026.112001_bib13","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","article-title":"Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial","volume":"29","author":"Shah","year":"2023","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.ejso.2026.112001_bib14","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1007\/s10120-024-01466-w","article-title":"Bemarituzumab as first-line treatment for locally advanced or metastatic gastric\/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial","volume":"27","author":"Wainberg","year":"2024","journal-title":"Gastric Cancer"},{"issue":"11","key":"10.1016\/j.ejso.2026.112001_bib15","article-title":"Profiling complete regression after pre-operative therapy in gastric cancer patients using clinical and pathological data","volume":"49","author":"Biondi","year":"2023"},{"key":"10.1016\/j.ejso.2026.112001_bib16","doi-asserted-by":"crossref","DOI":"10.7573\/dic.2024-10-7","article-title":"Real-life effectiveness of FLOT in resectable gastric cancer: existing challenges","volume":"14","author":"Serra","year":"2025","journal-title":"Drugs Context"},{"issue":"3","key":"10.1016\/j.ejso.2026.112001_bib17","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s40801-019-0159-z","article-title":"From clinical trial efficacy to real-life effectiveness: why conventional metrics do not work","volume":"6","author":"Boissel","year":"2019","journal-title":"Drugs Real World Outcomes"},{"issue":"11","key":"10.1016\/j.ejso.2026.112001_bib18","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/S1470-2045(18)30686-7","article-title":"DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis","volume":"19","author":"Henricks","year":"2018","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.ejso.2026.112001_bib19","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/ijc.34511","article-title":"Perioperative therapy with FLOT4 significantly increases survival in patients with gastroesophageal and gastric cancer in a large real-world cohort","volume":"153","author":"M\u00f6hring","year":"2023","journal-title":"Int J Cancer"},{"issue":"13","key":"10.1016\/j.ejso.2026.112001_bib20","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.3390\/cancers15133342","article-title":"Impact of signet-ring cell histology in the management of patients with non-metastatic gastric cancer: results from a retrospective multicenter analysis comparing FLOT perioperative chemotherapy vs. surgery followed by adjuvant chemotherapy","volume":"15","author":"Giampieri","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.ejso.2026.112001_bib21","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/jso.25959","article-title":"A detailed analysis of the recurrence timing and pattern after curative surgery in patients undergoing neoadjuvant therapy or upfront surgery for gastric cancer","volume":"122","author":"Agnes","year":"2020","journal-title":"J Surg Oncol"},{"issue":"3","key":"10.1016\/j.ejso.2026.112001_bib22","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s10120-021-01268-4","article-title":"Development of the PERI-gastric (PEritoneal recurrence index) and PERI-gram (peritoneal recurrence index NomoGRAM) for predicting the risk of metachronous peritoneal carcinomatosis after gastrectomy with curative intent for gastric cancer","volume":"25","author":"Agnes","year":"2022","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.ejso.2026.112001_bib23","article-title":"Prognostic indicators of preoperative fluorouracil, leucovorin, oxaliplatin, and docetaxel efficacy in locally advanced gastroesophageal and gastric cancer: integrating biomarker analysis and clinicopathological factors","volume":"9","author":"Jubashi","year":"2025","journal-title":"JCO Precis Oncol"},{"issue":"4","key":"10.1016\/j.ejso.2026.112001_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2024.108003","article-title":"Correlation of primary tumor volume and histopathologic response following neoadjuvant treatment of esophageal adenocarcinoma","volume":"50","author":"Bremm","year":"2024","journal-title":"Eur J Surg Oncol"},{"issue":"2","key":"10.1016\/j.ejso.2026.112001_bib25","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ejso.2021.08.016","article-title":"Expression of programmed cell death protein 1 (PD-1) and programmed cell death 1 ligand (PD-L1) in adenocarcinomas of the gastroesophageal junction change significantly after neoadjuvant treatment","volume":"48","author":"Jomrich","year":"2022","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2026.112001_bib26","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s12957-025-03828-9","article-title":"Radiomic-based models are able to predict the pathologic response to different neoadjuvant chemotherapy regimens in patients with gastric and gastroesophageal cancer: a cohort study","volume":"23","author":"Agnes","year":"2025","journal-title":"World J Surg Oncol"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798326006207?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798326006207?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T12:44:13Z","timestamp":1793364253000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798326006207"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0748798326006207"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2026.112001","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prediction of perioperative FLOT outcomes in Resectable Gastric and GEJ Adenocarcinoma with pathologic and molecular features: A Retrospective Real-World Cohort Study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2026.112001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"112001"}}